Developer docs
API playgroundTry for free, no card

Search company profiles

Biobot Analytics

Full company profile

uuid000035x

Namestring
Biobot Analytics
Legal namestring
Biobot Analytics, Inc.
Websiteurl
biobot.io
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Biobot Analytics is a Cambridge, Massachusetts-based wastewater epidemiology company that operates the largest US wastewater intelligence network, sampling hundreds of treatment facilities across all 50 states, the District of Columbia, US territories, and tribal territories. Its platform combines nationwide sampling logistics, molecular lab analysis (including genomic sequencing for SARS-CoV-2 and influenza A/B), and an AI-driven predictive analytics layer branded Biobot Advance to deliver weekly ZIP- and county-level data on more than 50 health trends spanning respiratory, gastrointestinal, and arboviral pathogens (e.g., SARS-CoV-2, RSV, influenza A/B, HMPV, mpox, norovirus, H5N1) and an expanding panel of substances (fentanyl, xylazine, methamphetamine, cocaine, benzodiazepines, naloxone, and other opioid and stimulant classes). Data is delivered through the secure explore.biobot.io dashboard, CSV downloads, and API keys, with a published turnaround of 3–5 days from sample collection to insight.

Biobot monetizes through four streams: (i) recurring state and local government subscriptions (e.g., Allegheny County, PA at $47,000/year for weekly substance surveillance, used to allocate ~$7M in opioid settlement funds), (ii) pharma and life sciences subscriptions to Biobot Advance, including API access for clinical trial site selection, real-world evidence, sales targeting, and programmatic media activation (anchored by the Pfizer/The Trade Desk use case), (iii) programmatic media data licensing via DSP integrations, and (iv) multi-year, multi-million-dollar federal contracts and grants with HHS/CDC, NIH/NIDA, and the White House Office of National Drug Control Policy. Go-to-market is sales-led enterprise (B2B/B2G) with a "Book a Demo" motion, supplemented by self-serve dashboard access and an API-first integration path for technical buyers.

The company is venture-backed by Y Combinator, The Engine, DCVC, Valor Equity Partners, Atreides Management, and Hyperplane, among others, and has raised approximately $33.6M in disclosed equity to date. Biobot is recognized by TIME 100 Most Influential Companies and TIME 100 Best Inventions (2022), CNBC Disruptor 50 (2022), and GovTech Top 100 (2019–2024), and its fentanyl-detection work was validated in a peer-reviewed Nature Water publication (2024). It operates with 11–50 employees from its Cambridge, MA headquarters and a Colorado-based laboratory.

Short descriptiontext

Biobot Analytics operates the largest US wastewater intelligence network, analyzing weekly samples from hundreds of sites for 50+ pathogens and substances, and selling predictive health data and AI-driven forecasts to federal/state governments, pharma, and life sciences customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wastewater epidemiology, public health intelligence, disease surveillance data, substance use monitoring, population health analytics
Industry4 codes
PRIMARYHLAJABAI
Wastewater & Environmental Pathogen Surveillance
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAJAJAB
Population Health Surveillance & Epidemiologic Analytics
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Statistics, Vital Records & Population Health Analytics
SECONDARYHLAJABAM
Modeling, Forecasting & Risk Assessment for Outbreaks
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAJAIAK
Public Health Genomics & Sequencing (WGS/Metagenomics) Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
NAICS code1 code
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Wastewater Epidemiology Intelligence
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Wastewater Monitoring Subscriptions (State & Local Government)
TypeSubscription Recurring
Description

Recurring annual contracts for ongoing wastewater surveillance covering sampling logistics, lab analysis, and access to data dashboards. Public reference pricing: Allegheny County, PA pays $47,000 annually for weekly surveillance of fentanyl, xylazine, ketamine, and medetomidine in the regional drug supply.

post-gazette.com
2Pharma & Life Sciences Data Subscriptions (Biobot Advance)
TypeSubscription Recurring
Description

Subscription or licensed access to Biobot Advance predictive wastewater intelligence for pharmaceutical and life sciences customers, including ZIP/county-level forecasts, hotspot identification, clinical trial site selection, R&D and real-world evidence support, and API integration for downstream use cases.

biobot.io
3Programmatic Media Data Licensing
TypeData Monetisation
Description

Integration of Biobot's regional disease trend data into demand-side platforms (DSPs) such as The Trade Desk for precision targeting of advertising campaigns. Powers pharma direct-to-consumer and clinical trial recruitment campaigns with measurable uplifts in click rate, visit action, and coupon download.

biobot.io
4Federal Government Contracts and Custom Analytics
TypeProfessional Services
Description

Federal contracts and grants (HHS, CDC, NIH/NIDA SBIR, ONDCP) covering nationwide wastewater surveillance, custom reporting, lab analysis, and program evaluation. Multi-million-dollar, multi-year engagements with program-specific deliverables.

biobot.io
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Quote-based enterprise subscription; not publicly disclosed
ModelOtherBilling cadenceAnnual
Notes

Pricing is custom and provided after a demo request. Public reference: Allegheny County, PA pays $47,000 annually for weekly wastewater surveillance of fentanyl, xylazine, ketamine, and medetomidine. Federal contracts (HHS, CDC, NIH/NIDA, ONDCP) are multi-year, multi-million-dollar engagements negotiated via RFP.

biobot.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Biobot Advance
Description

An AI-driven predictive analytics offering for pharmaceutical and life sciences customers, built on the world's largest wastewater dataset to provide geographically granular disease activity forecasts.

biobot.io
Core offering1 text field

Biobot Analytics operates a wastewater-based epidemiology platform that collects samples from hundreds of US wastewater treatment plants, performs molecular and genomic lab analysis, and delivers privacy-preserving population-level intelligence on 50+ health trends (respiratory, gastrointestinal, and arboviral pathogens plus opioids, stimulants, and treatment medications). Customers access weekly ZIP-, county-, and national-level data and predictive forecasts through interactive dashboards, CSV downloads, and an API, supporting government biosecurity, public-health surveillance, and pharmaceutical commercial and clinical-trial use cases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Detects shifts in fentanyl use 15 months ahead of traditional overdose reporting systems
+4 more records
Product overview1 text field

Biobot Analytics operates a single integrated wastewater intelligence platform composed of several named offerings: the core Biobot Wastewater Intelligence Platform (which analyzes more than 50 health trends including respiratory pathogens, gastrointestinal pathogens, arboviruses, opioids, stimulants, and treatment medications) sits at the center, with the customer-facing Biobot Explore dashboard/API portal as the access layer, Biobot Advance as the AI-driven analytics module for Pharma & Life Sciences customers, Biobot Risk Reports as the public weekly surveillance publication, and segment-specific solutions for Federal Government, State and Local Government, and Wastewater Treatment Plants that tailor the same underlying platform to each customer type.

Product and service6 records
1Biobot Wastewater Intelligence Platform
CategoryWastewater Epidemiology Platform
Description

Core platform providing real-time, privacy-first population-level wastewater intelligence across more than 50 health trends, including respiratory, gastrointestinal, and arboviral pathogens plus opioids, stimulants, benzodiazepines, and substance-use treatment medications. Accessible via secure dashboards (explore.biobot.io), CSV downloads, map visualizations, and API.

2Biobot Advance
CategoryPharma & Life Sciences Analytics
Description

AI-driven predictive analytics product offering a predictive, geographically granular view of disease activity for pharmaceutical and life sciences customers. Used to accelerate clinical trial site activation and enrollment, generate real-world evidence for R&D, target sales and marketing spend, and feed programmatic media campaigns. Exposes ZIP- and county-level weekly data with predictive hotspot forecasting via dashboard, CSV, and API.

3Biobot for Federal Government
CategoryGovernment Surveillance Solution
Description

Federal-government focused offering that strengthens national security and biosecurity by providing real-time, nationwide wastewater intelligence for population health, emerging-threat detection, and substance-use surveillance. Weekly data is available for every US ZIP and county, with API/CSV/map access for integration with CDC, HHS, DoD, and other federal frameworks.

4Biobot for State and Local Government
CategoryGovernment Surveillance Solution
Description

State and local public-health offering providing early, community-level wastewater intelligence for outbreak detection, emergency preparedness, program evaluation, and overdose-risk monitoring. Allows jurisdictions to compare local data with regional and national trends and receive tailored alerts by pathogen or geography.

5Biobot for Wastewater Treatment Plants
CategoryUtility Sampling Partnership
Description

Offering for wastewater treatment plant partners that turns existing infrastructure into a community health intelligence network. Provides sampling kits, logistics, lab analysis with 3–5 day turnaround, data dashboards, customizable alerts, and reporting for population health, substance use, and substance-use-disorder treatment monitoring.

6Biobot Explore (Customer Dashboard & API Portal)
CategoryData Access Platform
Description

Secure online portal where customers log in to access Biobot's interactive dashboards, generate and manage API keys for automated data access, download CSV files, and explore ZIP/county-level wastewater intelligence.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1White House Office of National Drug Control Policy (ONDCP)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Awarded a contract in January 2026 to deliver nationwide wastewater intelligence on substance use trends, covering more than 20 chemical targets including opioids, stimulants, and treatment medications. Builds on Biobot's prior work with NIDA (2020–2024). Data is used by federal and local officials to guide overdose prevention resources, identify drug trafficking hotspots, and enable earlier intervention.

prnewswire.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-09-21
Description

Phase III SBIR contract awarded in September 2023 for nationwide wastewater-based monitoring of drugs and overdose reversal agents. Analyzes wastewater from 70 communities for substances like opioids, stimulants, xylazine, and naloxone, informing public health interventions. Also funded a year-long pilot (September 2023–August 2024) analyzing weekly samples from 76 locations across 41 US states, serving approximately 20 million people, with peer-reviewed findings published in Nature Water.

3HHS (US Department of Health and Human Services)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Phase 1 and Phase 2 of the National Wastewater Monitoring Program (May–August 2021). Biobot processed more than 4,800 wastewater samples from 318 wastewater treatment facilities across all 50 states, DC, 2 US territories, and 7 tribal territories, representing over 90 million people (27% of the US population). Biobot built a custom surveillance dashboard with de-identified data per HIPAA and CDC guidelines.

biobot.io
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Partner on the National Wastewater Surveillance System (NWSS). Biobot's nationwide passive network provides the CDC with population-level data for tracking emerging infectious disease threats, including SARS-CoV-2, influenza A/B, RSV, HMPV, mpox, and norovirus.

Strategic tierCoreTypeTechnology or Integration
Description

Technology integration partner. Biobot's regional disease trend data is integrated into The Trade Desk's DSP for precision targeting of advertising campaigns, including Pfizer's flu vaccine trial recruitment campaign. Listed in Biobot's 'our partners' section on the homepage.

6State of Massachusetts
Strategic tierMinorTypeStrategic or Co-development Partner
Description

State government partner with logo displayed in Biobot's 'our partners' section on the homepage, indicating a state-level public health partnership for wastewater-based disease monitoring.

biobot.io
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Alphabet-owned life-sciences technology company that built and operated a nationwide wastewater surveillance network for SARS-CoV-2 during the COVID-19 emergency. Directly comparable to Biobot's HHS/CDC-era federal public-health wastewater intelligence offering, though Verily has broader ambitions across precision health and clinical research.

TypeDirect peer
Description

Specialized wastewater-based epidemiology lab offering RT-PCR testing services for SARS-CoV-2, influenza, RSV, and other pathogens to communities and utilities across the US. Directly competes with Biobot in the local and state public-health surveillance market with a similar lab-based service model.

TypeDirect peer
Description

Provider of qPCR-based molecular testing kits and services for wastewater, environmental, and clinical pathogen detection. Comparable to Biobot's lab assay capability and target menu (pathogens, process monitoring), with a stronger international footprint in industrial and environmental water testing.

TypeBroad incumbent
Description

Public synthetic biology platform whose Concentric biosecurity business provides pathogen surveillance, including wastewater monitoring, for government and public-health customers. Comparable as a broader biosecurity incumbent with overlapping wastewater and pathogen intelligence capabilities, though Ginkgo's focus extends well beyond wastewater.

TypeDirect peer
Description

Wastewater epidemiology and environmental testing firm serving municipalities, utilities, and public-health agencies. Comparable to Biobot on the wastewater sampling, lab analysis, and reporting layer, though typically focused on smaller-scale municipal deployments rather than nationwide federal contracts.

6CSO Analytic
TypeRegional player
Description

Italian wastewater epidemiology analytics company operating in Europe, providing population-level drug-use and disease intelligence similar to Biobot Advance. Highly comparable in methodology and use cases (opioids, stimulants, public-health agencies), but focused on European geographies where Biobot does not operate.

TypeEmerging player
Description

Clinical infectious-disease diagnostics company using next-generation sequencing of blood samples to detect pathogens. Comparable to Biobot as a pathogen intelligence platform applying advanced molecular and AI methods to public-health-adjacent use cases, though Karius operates in clinical rather than wastewater samples.

TypeEmerging player
Description

Population-scale health testing and analytics platform offering infectious disease, genetic, and public-health testing infrastructure for employers, governments, and pharma. Comparable to Biobot's population-level health intelligence and federal/state contract positioning, though Color focuses on individual-level diagnostics rather than pooled wastewater sampling.

TypeBroad incumbent
Description

Healthcare data and diagnostics platform serving physician practices, payers, and pharma with point-of-care testing and analytics. Adjacent comparator to Biobot Advance's pharma commercial and clinical-trial use cases, sharing a similar SaaS-meets-diagnostics GTM into life sciences customers.

TypeOthers
Description

Public-sector surveillance program built in partnership with Biobot and other state and academic labs to coordinate nationwide wastewater monitoring for SARS-CoV-2 and other pathogens. Not a commercial competitor per se, but a structural counterparty whose institutionalization and multi-vendor evolution directly shapes Biobot's federal pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biobot Analytics

Wastewater Epidemiology Intelligencebiobot.io

Biobot Analytics operates the largest US wastewater intelligence network, analyzing weekly samples from hundreds of sites for 50+ pathogens and substances, and selling predictive health data and AI-driven forecasts to federal/state governments, pharma, and life sciences customers.

What Biobot Analytics does

Biobot Analytics is a Cambridge, Massachusetts-based wastewater epidemiology company that operates the largest US wastewater intelligence network, sampling hundreds of treatment facilities across all 50 states, the District of Columbia, US territories, and tribal territories. Its platform combines nationwide sampling logistics, molecular lab analysis (including genomic sequencing for SARS-CoV-2 and influenza A/B), and an AI-driven predictive analytics layer branded Biobot Advance to deliver weekly ZIP- and county-level data on more than 50 health trends spanning respiratory, gastrointestinal, and arboviral pathogens (e.g., SARS-CoV-2, RSV, influenza A/B, HMPV, mpox, norovirus, H5N1) and an expanding panel of substances (fentanyl, xylazine, methamphetamine, cocaine, benzodiazepines, naloxone, and other opioid and stimulant classes). Data is delivered through the secure explore.biobot.io dashboard, CSV downloads, and API keys, with a published turnaround of 3–5 days from sample collection to insight.

Biobot monetizes through four streams: (i) recurring state and local government subscriptions (e.g., Allegheny County, PA at $47,000/year for weekly substance surveillance, used to allocate ~$7M in opioid settlement funds), (ii) pharma and life sciences subscriptions to Biobot Advance, including API access for clinical trial site selection, real-world evidence, sales targeting, and programmatic media activation (anchored by the Pfizer/The Trade Desk use case), (iii) programmatic media data licensing via DSP integrations, and (iv) multi-year, multi-million-dollar federal contracts and grants with HHS/CDC, NIH/NIDA, and the White House Office of National Drug Control Policy. Go-to-market is sales-led enterprise (B2B/B2G) with a "Book a Demo" motion, supplemented by self-serve dashboard access and an API-first integration path for technical buyers.

The company is venture-backed by Y Combinator, The Engine, DCVC, Valor Equity Partners, Atreides Management, and Hyperplane, among others, and has raised approximately $33.6M in disclosed equity to date. Biobot is recognized by TIME 100 Most Influential Companies and TIME 100 Best Inventions (2022), CNBC Disruptor 50 (2022), and GovTech Top 100 (2019–2024), and its fentanyl-detection work was validated in a peer-reviewed Nature Water publication (2024). It operates with 11–50 employees from its Cambridge, MA headquarters and a Colorado-based laboratory.

Biobot Analytics firmographics

Firmographics
Name
Biobot Analytics
Legal name
Biobot Analytics, Inc.
Website
https://biobot.io
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Biobot Analytics operates the largest US wastewater intelligence network, analyzing weekly samples from hundreds of sites for 50+ pathogens and substances, and selling predictive health data and AI-driven forecasts to federal/state governments, pharma, and life sciences customers.
Ownership category
akta.pro rank

Biobot Analytics industry classification

Industry
Product category
Wastewater Epidemiology Intelligence
NAICS
Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAJABAI
Wastewater & Environmental Pathogen Surveillance
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAJAJAB
Population Health Surveillance & Epidemiologic Analytics
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Statistics, Vital Records & Population Health Analytics
SECONDARYHLAJABAM
Modeling, Forecasting & Risk Assessment for Outbreaks
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAJAIAK
Public Health Genomics & Sequencing (WGS/Metagenomics) Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

  • Wastewater epidemiology
  • Public health intelligence
  • Disease surveillance data
  • Substance use monitoring
  • Population health analytics

Where Biobot Analytics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Biobot Analytics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Wastewater Monitoring Subscriptions (State & Local Government): Recurring annual contracts for ongoing wastewater surveillance covering sampling logistics, lab analysis, and access to data dashboards. Public reference pricing: Allegheny County, PA pays $47,000 annually for weekly surveillance of fentanyl, xylazine, ketamine, and medetomidine in the regional drug supply.
  2. Pharma & Life Sciences Data Subscriptions (Biobot Advance): Subscription or licensed access to Biobot Advance predictive wastewater intelligence for pharmaceutical and life sciences customers, including ZIP/county-level forecasts, hotspot identification, clinical trial site selection, R&D and real-world evidence support, and API integration for downstream use cases.
  3. Programmatic Media Data Licensing: Integration of Biobot's regional disease trend data into demand-side platforms (DSPs) such as The Trade Desk for precision targeting of advertising campaigns. Powers pharma direct-to-consumer and clinical trial recruitment campaigns with measurable uplifts in click rate, visit action, and coupon download.
  4. Federal Government Contracts and Custom Analytics: Federal contracts and grants (HHS, CDC, NIH/NIDA SBIR, ONDCP) covering nationwide wastewater surveillance, custom reporting, lab analysis, and program evaluation. Multi-million-dollar, multi-year engagements with program-specific deliverables.

Pricing tiers

ModelBillingPrice
OtherAnnualQuote-based enterprise subscription; not publicly disclosed

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Biobot Analytics product offering

Product offering

Core offering

Biobot Analytics operates a wastewater-based epidemiology platform that collects samples from hundreds of US wastewater treatment plants, performs molecular and genomic lab analysis, and delivers privacy-preserving population-level intelligence on 50+ health trends (respiratory, gastrointestinal, and arboviral pathogens plus opioids, stimulants, and treatment medications). Customers access weekly ZIP-, county-, and national-level data and predictive forecasts through interactive dashboards, CSV downloads, and an API, supporting government biosecurity, public-health surveillance, and pharmaceutical commercial and clinical-trial use cases.

Product overview

Biobot Analytics operates a single integrated wastewater intelligence platform composed of several named offerings: the core Biobot Wastewater Intelligence Platform (which analyzes more than 50 health trends including respiratory pathogens, gastrointestinal pathogens, arboviruses, opioids, stimulants, and treatment medications) sits at the center, with the customer-facing Biobot Explore dashboard/API portal as the access layer, Biobot Advance as the AI-driven analytics module for Pharma & Life Sciences customers, Biobot Risk Reports as the public weekly surveillance publication, and segment-specific solutions for Federal Government, State and Local Government, and Wastewater Treatment Plants that tailor the same underlying platform to each customer type.

Differentiator

Problem solved

Functional benefit

Brands

  • Biobot Advance: An AI-driven predictive analytics offering for pharmaceutical and life sciences customers, built on the world's largest wastewater dataset to provide geographically granular disease activity forecasts.

Products and services

  • Biobot Wastewater Intelligence Platform Core platform providing real-time, privacy-first population-level wastewater intelligence across more than 50 health trends, including respiratory, gastrointestinal, and arboviral pathogens plus opioids, stimulants, benzodiazepines, and substance-use treatment medications. Accessible via secure dashboards (explore.biobot.io), CSV downloads, map visualizations, and API.
  • Biobot Advance AI-driven predictive analytics product offering a predictive, geographically granular view of disease activity for pharmaceutical and life sciences customers. Used to accelerate clinical trial site activation and enrollment, generate real-world evidence for R&D, target sales and marketing spend, and feed programmatic media campaigns. Exposes ZIP- and county-level weekly data with predictive hotspot forecasting via dashboard, CSV, and API.
  • Biobot for Federal Government Federal-government focused offering that strengthens national security and biosecurity by providing real-time, nationwide wastewater intelligence for population health, emerging-threat detection, and substance-use surveillance. Weekly data is available for every US ZIP and county, with API/CSV/map access for integration with CDC, HHS, DoD, and other federal frameworks.
  • Biobot for State and Local Government State and local public-health offering providing early, community-level wastewater intelligence for outbreak detection, emergency preparedness, program evaluation, and overdose-risk monitoring. Allows jurisdictions to compare local data with regional and national trends and receive tailored alerts by pathogen or geography.
  • Biobot for Wastewater Treatment Plants Offering for wastewater treatment plant partners that turns existing infrastructure into a community health intelligence network. Provides sampling kits, logistics, lab analysis with 3–5 day turnaround, data dashboards, customizable alerts, and reporting for population health, substance use, and substance-use-disorder treatment monitoring.
  • Biobot Explore (Customer Dashboard & API Portal) Secure online portal where customers log in to access Biobot's interactive dashboards, generate and manage API keys for automated data access, download CSV files, and explore ZIP/county-level wastewater intelligence.

Quantifiable outcome

  • Detects shifts in fentanyl use 15 months ahead of traditional overdose reporting systems
  • +4 more outcomes

Companies that use Biobot Analytics

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Biobot Analytics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature6 records

Biobot Analytics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

  • White House Office of National Drug Control Policy (ONDCP)flagshipStrategic or Co-development Partner · 7 January 2026Awarded a contract in January 2026 to deliver nationwide wastewater intelligence on substance use trends, covering more than 20 chemical targets including opioids, stimulants, and treatment medications. Builds on Biobot's prior work with NIDA (2020–2024). Data is used by federal and local officials to guide overdose prevention resources, identify drug trafficking hotspots, and enable earlier intervention.
  • NIH/NIDA (National Institute on Drug Abuse)flagshipStrategic or Co-development Partner · 21 September 2023Phase III SBIR contract awarded in September 2023 for nationwide wastewater-based monitoring of drugs and overdose reversal agents. Analyzes wastewater from 70 communities for substances like opioids, stimulants, xylazine, and naloxone, informing public health interventions. Also funded a year-long pilot (September 2023–August 2024) analyzing weekly samples from 76 locations across 41 US states, serving approximately 20 million people, with peer-reviewed findings published in Nature Water.
  • HHS (US Department of Health and Human Services)flagshipStrategic or Co-development PartnerPhase 1 and Phase 2 of the National Wastewater Monitoring Program (May–August 2021). Biobot processed more than 4,800 wastewater samples from 318 wastewater treatment facilities across all 50 states, DC, 2 US territories, and 7 tribal territories, representing over 90 million people (27% of the US population). Biobot built a custom surveillance dashboard with de-identified data per HIPAA and CDC guidelines.
  • CDC (Centers for Disease Control and Prevention)flagshipStrategic or Co-development PartnerPartner on the National Wastewater Surveillance System (NWSS). Biobot's nationwide passive network provides the CDC with population-level data for tracking emerging infectious disease threats, including SARS-CoV-2, influenza A/B, RSV, HMPV, mpox, and norovirus.
  • The Trade DeskcoreTechnology or IntegrationTechnology integration partner. Biobot's regional disease trend data is integrated into The Trade Desk's DSP for precision targeting of advertising campaigns, including Pfizer's flu vaccine trial recruitment campaign. Listed in Biobot's 'our partners' section on the homepage.
  • State of MassachusettsminorStrategic or Co-development PartnerState government partner with logo displayed in Biobot's 'our partners' section on the homepage, indicating a state-level public health partnership for wastewater-based disease monitoring.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Biobot Analytics competitors and assessment

Company assessment

Direct peers

  • Verily Life Sciences: Alphabet-owned life-sciences technology company that built and operated a nationwide wastewater surveillance network for SARS-CoV-2 during the COVID-19 emergency. Directly comparable to Biobot's HHS/CDC-era federal public-health wastewater intelligence offering, though Verily has broader ambitions across precision health and clinical research.
  • GT Molecular: Specialized wastewater-based epidemiology lab offering RT-PCR testing services for SARS-CoV-2, influenza, RSV, and other pathogens to communities and utilities across the US. Directly competes with Biobot in the local and state public-health surveillance market with a similar lab-based service model.
  • Luminultra: Provider of qPCR-based molecular testing kits and services for wastewater, environmental, and clinical pathogen detection. Comparable to Biobot's lab assay capability and target menu (pathogens, process monitoring), with a stronger international footprint in industrial and environmental water testing.
  • Aqua Analytics: Wastewater epidemiology and environmental testing firm serving municipalities, utilities, and public-health agencies. Comparable to Biobot on the wastewater sampling, lab analysis, and reporting layer, though typically focused on smaller-scale municipal deployments rather than nationwide federal contracts.

Broad incumbents

  • Ginkgo Bioworks (Concentric by Ginkgo): Public synthetic biology platform whose Concentric biosecurity business provides pathogen surveillance, including wastewater monitoring, for government and public-health customers. Comparable as a broader biosecurity incumbent with overlapping wastewater and pathogen intelligence capabilities, though Ginkgo's focus extends well beyond wastewater.
  • Athelas: Healthcare data and diagnostics platform serving physician practices, payers, and pharma with point-of-care testing and analytics. Adjacent comparator to Biobot Advance's pharma commercial and clinical-trial use cases, sharing a similar SaaS-meets-diagnostics GTM into life sciences customers.

Regional players

  • CSO Analytic: Italian wastewater epidemiology analytics company operating in Europe, providing population-level drug-use and disease intelligence similar to Biobot Advance. Highly comparable in methodology and use cases (opioids, stimulants, public-health agencies), but focused on European geographies where Biobot does not operate.

Emerging players

  • Karius: Clinical infectious-disease diagnostics company using next-generation sequencing of blood samples to detect pathogens. Comparable to Biobot as a pathogen intelligence platform applying advanced molecular and AI methods to public-health-adjacent use cases, though Karius operates in clinical rather than wastewater samples.
  • Color Health: Population-scale health testing and analytics platform offering infectious disease, genetic, and public-health testing infrastructure for employers, governments, and pharma. Comparable to Biobot's population-level health intelligence and federal/state contract positioning, though Color focuses on individual-level diagnostics rather than pooled wastewater sampling.

Others

  • CDC National Wastewater Surveillance System (NWSS): Public-sector surveillance program built in partnership with Biobot and other state and academic labs to coordinate nationwide wastewater monitoring for SARS-CoV-2 and other pathogens. Not a commercial competitor per se, but a structural counterparty whose institutionalization and multi-vendor evolution directly shapes Biobot's federal pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Biobot Analytics social profiles

Digital presence

Biobot Analytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biobot Analytics leadership team

Management profile

Number of profiles

Profiles4 records

Biobot Analytics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biobot Analytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biobot Analytics

What does Biobot Analytics do?

Biobot Analytics operates a wastewater-based epidemiology platform that collects samples from hundreds of US wastewater treatment plants, performs molecular and genomic lab analysis, and delivers privacy-preserving population-level intelligence on 50+ health trends (respiratory, gastrointestinal, and arboviral pathogens plus opioids, stimulants, and treatment medications). Customers access weekly ZIP-, county-, and national-level data and predictive forecasts through interactive dashboards, CSV downloads, and an API, supporting government biosecurity, public-health surveillance, and pharmaceutical commercial and clinical-trial use cases.

Is Biobot Analytics a public or private company?

Biobot Analytics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biobot Analytics founded?

Biobot Analytics was founded in 2017. It employs 11 to 50 people.

Where is Biobot Analytics based?

Biobot Analytics is headquartered in Cambridge, United States, in the North America region.

How does Biobot Analytics make money?

Four revenue lines are on record. Wastewater Monitoring Subscriptions (State & Local Government) is the primary driver. The others are pharma & Life Sciences Data Subscriptions (Biobot Advance), programmatic Media Data Licensing and federal Government Contracts and Custom Analytics.

Who are Biobot Analytics's main competitors?

Direct peers on record are Verily Life Sciences, GT Molecular, Luminultra and Aqua Analytics. Broad incumbents are Ginkgo Bioworks (Concentric by Ginkgo) and Athelas. CSO Analytic is listed as a regional player. Emerging players are Karius and Color Health. CDC National Wastewater Surveillance System (NWSS) is listed as an others.

Does Biobot Analytics have an API?

Yes. Biobot offers a public/partner-facing API that allows customers to programmatically access its wastewater intelligence data, including pathogen and substance use trends at ZIP and county granularity. Authentication is via account-based API keys (managed through the explore.biobot.io portal). The API supports automated ingestion into internal analytics platforms, demand-side platforms (DSPs), and government frameworks (e.g., CDC, HHS, DoD). Data is also accessible via secure dashboards and CSV downloads. Developer documentation is at explore.biobot.io.

What industry is Biobot Analytics in?

Biobot Analytics's product category is Wastewater Epidemiology Intelligence. Its primary akta.pro industry code is HLAJABAI, Wastewater & Environmental Pathogen Surveillance, with a secondary code of HLAJAJAB, Population Health Surveillance & Epidemiologic Analytics. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Las Vegas Review-JournalNevada ranks high for levels of meth, fentanyl found in wastewater, report saysThe Office of National Drug Control Policy released its first-ever 'Wastewater Analytics' report showing that Nevada's Clark and Washoe counties contained some of the highest concentrations of methamphetamine and fentanyl in the country during the monitoring period from January 2025 to April 2026. Biobot Analytics collected and analyzed monthly wastewater samples from 100 counties, finding that while nationwide drug levels are declining, Nevada consistently ranked in the top 20 percent of testing sites for high concentrations of both drugs. The federal report is part of the Trump administration's effort to combat drug overdoses, which have declined approximately 14 percent year-over-year to about 70,000 deaths in 2025.BioWorldFinancings for June 30, 2026On June 30, 2026, biopharma and med-tech companies including 4DMT, Akari, Biobot, and Neurolife raised money through public or private financings. The list of companies is provided in the BioWorld brief.PR NewswireFindings from Biobot's Nationwide Wastewater Monitoring Program for Prescription and High-Risk Substances published in Nature WaterBiobot Analytics published peer-reviewed findings in Nature Water demonstrating that its NIH/NIDA-funded nationwide wastewater monitoring pilot can detect shifts in fentanyl use 15 months ahead of traditional overdose reporting systems. The year-long initiative (September 2023–August 2024) analyzed weekly wastewater samples from 76 locations across 41 US states, serving approximately 20 million people, testing for fentanyl, methamphetamine, cocaine, xylazine, and naloxone. Participating communities leveraged the real-time data to guide public health action, including Laredo, Texas launching a community outreach campaign that distributed naloxone to over 2,000 households.The Seattle TimesCities and schools are testing wastewater for illicit drugsCities and schools across the United States are testing wastewater for illicit drugs as a public health strategy to detect emerging drug threats and prevent overdoses, with Tempe, Arizona pioneering the approach in 2018. The Trump administration's Office of National Drug Control Policy has endorsed the method, contracting with Biobot Analytics to test sewage for 20 substances at approximately 100 sites nationwide, while legislators in at least five states have proposed bills to fund wider expansion. The approach has sparked privacy debates, with critics raising concerns about consent, neighborhood stigmatization, and potential law enforcement overreach, though proponents argue it reveals drug use across all socioeconomic areas.CambridgedayCambridge company helps White House track drug usage trends through wastewaterA Cambridge wastewater analytics company, Biobot Analytics, has partnered with the White House's Office of National Drug Control Policy to analyze wastewater data from across the U.S. to identify community-level drug use trends, especially for opioids and stimulants. The project, which began in September 2025 with a one-year contract, aims to detect drug use changes rapidly and help allocate public health resources accordingly.Pittsburgh Post-GazetteWhat’s in Allegheny County’s wastewater? Testing tracks fentanyl, xylazine and more flowing through Western Pa.Allegheny County has contracted with Biobot Analytics since March 2024 to conduct weekly wastewater surveillance tracking substances including fentanyl, xylazine, ketamine, and medetomidine in the regional drug supply, with samples collected by the Allegheny County Sewer Authority and analyzed at Biobot's Colorado lab. The county pays $47,000 annually for this service, which has directly informed the allocation of approximately $7 million in annual opioid settlement funds toward targeted interventions such as xylazine wound treatment and withdrawal management programs. Public health officials note that while wastewater monitoring provides valuable early warning signals about shifting drug trends, it represents only one component of a broader surveillance system that also includes emergency department data, overdose death tracking, and drug checking programs like those run by Prevention Point Pittsburgh.PR NewswireBiobot Analytics Selected by White House Office of National Drug Control Policy to Provide Nationwide Wastewater Intelligence on Substance Use TrendsBiobot Analytics has been awarded a contract by the White House Office of National Drug Control Policy to deliver nationwide wastewater-based substance use intelligence, covering more than 20 chemical targets including opioids, stimulants, and emerging compounds. The partnership builds on Biobot's prior work with the National Institute on Drug Abuse from 2020–2024, which demonstrated that wastewater analysis can detect drug use shifts months before traditional indicators. The data will be used to guide federal and local resource allocation, support overdose prevention efforts, and provide insights into drug trafficking activities.PressdemocratSonoma County launches online tool for monitoring real-time illegal drug trendsSonoma County health officials launched an online dashboard to monitor weekly real-time drug trends using wastewater data from the Laguna Wastewater Treatment Plant. The tool, developed in partnership with Biobot Analytics, tracks substances including fentanyl and methamphetamine, revealing that local concentrations of these drugs regularly exceed national averages.PR NewswireBiobot Analytics Announces New Funding Round Led by Valor Equity Partners; Expands Board of DirectorsBiobot Analytics announced a new funding round led by Valor Equity Partners, with participation from Atreides Management and Hyperplane. The capital will support expanding wastewater intelligence offerings and product development. New board members include Vivek Pattipati, Andrew Perlman, and Vivjan Myrto.SecSEC FORM DThe SEC filed a Form D notice for Biobot Analytics, Inc., a Delaware-incorporated biotechnology company, indicating a securities offering with a total amount of approximately $13.6 million. The offering is scheduled to begin on May 23, 2025, and involves equity, debt, and options securities.